نتائج البحث

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

• Source: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide,

تفاصيل العنوان

A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH)

• Source: A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and

تفاصيل العنوان

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

• Authors : Janssen Research & Development, LLC

• Source: A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab,

تفاصيل العنوان

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study.

• Authors : Choi YS; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.; Shim J

Subjects: Bortezomib*/Bortezomib*/Bortezomib*/administration & dosage ; Bortezomib*/Bortezomib*/Bortezomib*/therapeutic use ; Dexamethasone*/Dexamethasone*/Dexamethasone*/administration & dosage

• Source: Cancer research and treatment [Cancer Res Treat] 2025 Jan; Vol. 57 (1), pp. 267-279. Date of Electronic Publication: 2024 Jul 16.Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

• Source: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide,

تفاصيل العنوان

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis.

• Authors : Gao X; Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.; Feng Q

Subjects: Bortezomib*/Bortezomib*/Bortezomib*/pharmacology ; Bortezomib*/Bortezomib*/Bortezomib*/therapeutic use ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy

• Source: Journal of biomedical science [J Biomed Sci] 2025 Jan 20; Vol. 32 (1), pp. 9. Date of Electronic Publication: 2025 Jan 20.Publisher: BioMed Central Country of Publication: England NLM ID: 9421567 Publication Model: Electronic Cited Medium: Internet ISSN: 1423-0127

تفاصيل العنوان

Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma.

• Authors : Wang JX; Department of Hematology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, 518172, China.; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, National- Regional Key Technology Engineering Laboratory for Medical Ultrasound, Shenzhen University Medical School, Shenzhen, 518060, China.

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Bortezomib*/Bortezomib*/Bortezomib*/pharmacology ; Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/Drug Resistance, Neoplasm*/drug effects

• Source: Biology direct [Biol Direct] 2025 Jan 06; Vol. 20 (1), pp. 1. Date of Electronic Publication: 2025 Jan 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101258412 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6150

تفاصيل العنوان

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

• Source: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T)

تفاصيل العنوان

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

• Source: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and

تفاصيل العنوان

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

• Source: A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

تفاصيل العنوان